PIK3CA and breast carcinoma: Another inherent limitation of all mutation-based analysis is the infrequency of recurrent mutations in breast cancer besides TP53 and PIK3CA. Owing to limited sample number we collapsed mutations at a single gene level, thus excluding the possibility to assess the impact of different mutations at the single codon level.